Chief executive Vicky Taylor said the move was deeply disappointing but reflected the challenging conditions facing the sector.
“This is an incredibly difficult moment for our team and for the wider medical cannabis industry,” Taylor said.
“Helius was founded with a clear purpose – to provide high-quality, clinically trusted cannabis medicines that could genuinely improve patients’ lives.
“Unfortunately, the current commercial and regulatory environment has made it very challenging for manufacturers to operate sustainably at scale.
“Restrictions on market education haven’t enabled anyone in the industry to help as many patients as they potentially could.”
The voluntary administration does not impact the clinic business…